Virus activated killer immune cell (VAK) therapy - Binhui Biopharmaceutical
Latest Information Update: 29 May 2024
At a glance
- Originator Binhui Biopharmaceutical
- Class Antineoplastics; Cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Cell replacements; Immunologic cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase 0 Malignant pleural effusion